Morgan Stanley’s PHAXIAM Therapeutics S.A.. American Depositary Shares PHXM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-30
Closed -$2K 8181
2021
Q3
$2K Sell
30
-460
-94% -$25.8K ﹤0.01% 7696
2021
Q2
$24K Buy
+490
New +$30.3K ﹤0.01% 6949
2021
Q1
Sell
-10
Closed -$1K 7602
2020
Q4
$1K Buy
+10
New +$780 ﹤0.01% 6989

Other funds holding PHXM

Morgan Stanley's PHXM Position: Q4 2021 in Review

Morgan Stanley sold out of PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) in Q4 2021, closing a stake of 30 shares — an estimated $2K sold.

Morgan Stanley first reported a position in PHXM in Q4 2020 and held it in 3 quarters. The position peaked at $24K in Q2 2021. 9 funds tracked by Wall St. Rank hold PHXM as of Q4 2021.

  • Morgan Stanley reported no remaining PHAXIAM Therapeutics S.A.. American Depositary Shares position as of Q4 2021 after selling out during the quarter.
  • Morgan Stanley sold 30 PHAXIAM Therapeutics S.A.. American Depositary Shares shares in Q4 2021, an estimated $2K.
  • Morgan Stanley first reported a position in PHAXIAM Therapeutics S.A.. American Depositary Shares in Q4 2020 and held it in 3 quarters.
  • Morgan Stanley's PHAXIAM Therapeutics S.A.. American Depositary Shares position peaked at $24K in Q2 2021.
  • 9 funds tracked by Wall St. Rank held PHAXIAM Therapeutics S.A.. American Depositary Shares as of Q4 2021.

Based on Morgan Stanley's 13F filing for Q4 2021, filed 14 Feb 2022.